Age is an important risk factor for onset and sequelae of reversal reactions in Vietnamese patients with leprosy

Clinical Infectious Diseases

Volumn 44, Issue 1, 2007, Pages 33-40

  Ranque, Brigitte ^a   Nguyen, Van Thuc ^b   Vu, Hong Thai ^b   Nguyen, Thu Huong ^b   Nguyen, Ngoc Ba ^b   Pham, Xuan Khoa ^b   Schurr, Erwin ^c   Abel, Laurent ^a   Alcaïs, Alexandre ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Hospital for Dermato Venereology   (Viet Nam)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; CLINICAL FEATURE; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; HUMAN; INFECTION RISK; LEPROSY; LEPROSY EPIDEMIOLOGY; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MULTIVARIATE ANALYSIS; NEURITIS; ONSET AGE; PREVALENCE; PRIORITY JOURNAL; REVERSAL REACTION; RISK FACTOR; SENSORY DYSFUNCTION; SKIN DEFECT; VIET NAM;

ADOLESCENT; ADULT; AGE FACTORS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LEPROSY; LOGISTIC MODELS; MALE; MIDDLE AGED; NEURITIS; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SKIN; VIETNAM;

EID: 33845690070     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/509923     Document Type: Article

References (31)

1. World Health Organization. Global leprosy situation. Wkly Epidemiol Rec 2005; 80:113-24.
2. Meima A, Richardus JH, Habbema JD. Trends in leprosy case detection worldwide since 1985. Lepr Rev 2004; 75:19-33.
3. Britton WJ, Lockwood DN. Leprosy. Lancet 2004; 363:1209-19.
4. Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL. The continuing challenges of leprosy. Clin Microbiol Rev 2006; 19:338-81.
5. Ridley DS, Jopling WH. Classification of leprosy according to immunity: a five-group system. Int J Lepr Other Mycobact Dis 1966; 34: 255-73.
6. World Health Organization. Expert committee on leprosy: 6th report. World Health Organ Tech Rep Ser 1988; 768:1-51.
7. Lienhardt C, Fine PE. Type 1 reaction, neuritis and disability in leprosy: what is the current epidemiological situation? Lepr Rev 1994; 65:9-33.
8. Becx-Bleumink M, Berhe D. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Int J Lepr Other Mycobact Dis 1992; 60:173-84.
9. Van Brakel WH, Khawas IB, Lucas SB. Reactions in leprosy: an epidemiological study of 386 patients in West Nepal. Lepr Rev 1994; 65: 190-203.
10. Schreuder PA. The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1987-1995 [correction of 1978-1995]-II. reactions. Int J Lepr Other Mycobact Dis 1998; 66:159-69.
11. Sharma N, Koranne RV, Mendiratta V, Sharma RC. A study of leprosy reactions in a tertiary hospital in Delhi. J Dermatol 2004; 31:898-903.
12. Kumar B, Dogra S, Kaur I. Epidemiological characteristics of leprosy reactions: 15 years experience from north India. Int J Lepr Other Mycobact Dis 2004; 72:125-33.
13. Rose P, Waters MF. Reversal reactions in leprosy and their management. Lepr Rev 1991; 62:113-21.
14. Khanolkar-Young S, Rayment N, Brickell PM, et al. Tumour necrosis factor-alpha (TNF-α) synthesis is associated with the skin and peripheral nerve pathology of leprosy reversal reactions. Clin Exp Immunol 1995; 99:196-202.
15. Verhagen CE, Wierenga EA, Buffing AA, Chand MA, Faber WR, Das PK. Reversal reaction in borderline leprosy is associated with a polarized shift to type 1-like Mycobacterium leprae T cell reactivity in lesional skin: a follow-up study. J Immunol 1997; 159:4474-83.
16. Stefani MM, Martelli CM, Gillis TP, Krahenbuhl JL. In situ type 1 cytokine gene expression and mechanisms associated with early leprosy progression. J Infect Dis 2003; 188:1024-31.
17. Moraes MO, Sarno EN, Almeida AS, et al. Cytokine mRNA expression in leprosy: a possible role for interferon-gamma and interleukin-12 in reactions (RR and ENL). Scand J Immunol 1999; 50:541-9.
18. Moraes MO, Sampaio EP, Nery JA, Saraiva BC, Alvarenga FB, Sarno EN. Sequential erythema nodosum leprosum and reversal reaction with similar lesional cytokine mRNA patterns in a borderline leprosy patient. Br J Dermatol 2001; 144:175-81.
19. Britton WJ. The management of leprosy reversal reactions. Lepr Rev 1998; 69:225-34.
20. Roche PW, Theuvenet WJ, Britton WJ. Risk factors for type-1 reactions in borderline leprosy patients. Lancet 1991; 338:654-7.
21. Lockwood DN, Vinayakumar S, Stanley JN, McAdam KP, Colston MJ. Clinical features and outcome of reversal (type 1) reactions in Hyderabad, India. Int J Lepr Other Mycobact Dis 1993; 61:8-15.
22. de Rijk AJ, Gabre S, Byass P, Berhanu T. Field evaluation of WHO-MDT of fixed duration, at ALERT, Ethiopia: the AMFES project-II. reaction and neuritis during and after MDT in PB and MB leprosy patients. Lepr Rev 1994; 65:320-32.
23. Saunderson P, Gebre S, Byass P. Reversal reactions in the skin lesions of AMFES patients: incidence and risk factors. Lepr Rev 2000; 71: 309-17.
24. Mira MT, Alcais A, Nguyen VT, et al. Susceptibility to leprosy is associated with PARK2 and PACRG. Nature 2004; 427:636-40.
25. Mira MT, Alcais A, Di Pietrantonio T, et al. Segregation of HLA/TNF region is linked to leprosy clinical spectrum in families displaying mixed leprosy subtypes. Genes Immun 2003; 4:67-73.
26. World Health Organization. Chemotherapy of leprosy for control programmes. World Health Organ Tech Rep Ser 1982; 675:1-33.
27. Boerrigter G, Ponnighaus JM, Fine PE, Wilson RJ. Four-year follow-up results of a WHO-recommended multiple-drug regimen in paucibacillary leprosy patients in Malawi. Int J Lepr Other Mycobact Dis 1991; 59:255-61.
28. Adkins B, Leclerc C, Marshall-Clarke S. Neonatal adaptive immunity comes of age. Nat Rev Immunol 2004; 4:553-64.
29. + B cells control the IL-12-dependent Th1-priming capacity of neonatal DCs. Immunity 2005; 22:467-77.
30. Wilkinson RJ, Lockwood DN. Antigenic trigger for type 1 reaction in leprosy. J Infect 2005; 50:242-3.
31. Alcais A, Mira M, Casanova JL, Schurr E, Abel L. Genetic dissection of immunity in leprosy. Curr Opin Immunol 2005; 17:44-8.